142 related articles for article (PubMed ID: 24907019)
1. Treatment of paediatric APL: how does the therapeutic approach differ from adults?
Kutny MA; Gregory J; Feusner JH
Best Pract Res Clin Haematol; 2014 Mar; 27(1):69-78. PubMed ID: 24907019
[TBL] [Abstract][Full Text] [Related]
2. Can we say farewell to monitoring minimal residual disease in acute promyelocytic leukaemia?
Grimwade D; Jovanovic JV; Hills RK
Best Pract Res Clin Haematol; 2014 Mar; 27(1):53-61. PubMed ID: 24907017
[TBL] [Abstract][Full Text] [Related]
3. Have all-trans retinoic acid and arsenic trioxide replaced all-trans retinoic acid and anthracyclines in APL as standard of care.
Iland HJ; Wei A; Seymour JF
Best Pract Res Clin Haematol; 2014 Mar; 27(1):39-52. PubMed ID: 24907016
[TBL] [Abstract][Full Text] [Related]
4. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
5. Long-term efficacy of low-dose all-trans retinoic acid plus minimal chemotherapy induction followed by the addition of intravenous arsenic trioxide post-remission therapy in newly diagnosed acute promyelocytic leukaemia.
Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
Hematol Oncol; 2014 Mar; 32(1):40-6. PubMed ID: 23963734
[TBL] [Abstract][Full Text] [Related]
6. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study.
Kwong YL; Au WY; Chim CS; Pang A; Suen C; Liang R
Am J Hematol; 2001 Apr; 66(4):274-9. PubMed ID: 11279639
[TBL] [Abstract][Full Text] [Related]
7. Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.
Cheng Y; Zhang L; Wu J; Lu A; Wang B; Liu G
Eur J Haematol; 2013 Dec; 91(6):483-9. PubMed ID: 24033687
[TBL] [Abstract][Full Text] [Related]
8. Conventional induction and post-remission therapy in APL: have we arrived?
Sanz MA; Iacoboni G; Montesinos P
Best Pract Res Clin Haematol; 2014 Mar; 27(1):33-8. PubMed ID: 24907015
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of arsenic trioxide with or without all-trans retinoic acid for the treatment of acute promyelocytic leukemia: a meta-analysis.
Wang H; Chen XY; Wang BS; Rong ZX; Qi H; Chen HZ
Leuk Res; 2011 Sep; 35(9):1170-7. PubMed ID: 21774985
[TBL] [Abstract][Full Text] [Related]
10. Advances in therapies for acute promyelocytic leukemia.
Kamimura T; Miyamoto T; Harada M; Akashi K
Cancer Sci; 2011 Nov; 102(11):1929-37. PubMed ID: 21790894
[TBL] [Abstract][Full Text] [Related]
11. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
13. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention.
Esteve J; Escoda L; Martín G; Rubio V; Díaz-Mediavilla J; González M; Rivas C; Alvarez C; González San Miguel JD; Brunet S; Tomás JF; Tormo M; Sayas MJ; Sánchez Godoy P; Colomer D; Bolufer P; Sanz MA;
Leukemia; 2007 Mar; 21(3):446-52. PubMed ID: 17205057
[TBL] [Abstract][Full Text] [Related]
14. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
15. Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
Bally C; Fadlallah J; Leverger G; Bertrand Y; Robert A; Baruchel A; Guerci A; Recher C; Raffoux E; Thomas X; Leblanc T; Idres N; Cassinat B; Vey N; Chomienne C; Dombret H; Sanz M; Fenaux P; Adès L
J Clin Oncol; 2012 May; 30(14):1641-6. PubMed ID: 22473162
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with arsenic trioxide, all-trans retinoic acid, and chemotherapy in acute promyelocytic leukemia patients with various relapse risks.
Huang H; Qin Y; Xu R; You X; Teng R; Yang L; Xu M; Liu H
Leuk Res; 2012 Jul; 36(7):841-5. PubMed ID: 22534100
[TBL] [Abstract][Full Text] [Related]
17. Treatment of an acute promyelocytic leukemia relapse using arsenic trioxide and all-trans-retinoic in a 6-year-old child.
Rock N; Mattiello V; Judas C; Huezo-Diaz P; Bourquin JP; Gumy-Pause F; Ansari M
Pediatr Hematol Oncol; 2014 Mar; 31(2):143-8. PubMed ID: 24498972
[TBL] [Abstract][Full Text] [Related]
18. Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.
Kutny MA; Alonzo TA; Gerbing RB; Wang YC; Raimondi SC; Hirsch BA; Fu CH; Meshinchi S; Gamis AS; Feusner JH; Gregory JJ
J Clin Oncol; 2017 Sep; 35(26):3021-3029. PubMed ID: 28767288
[TBL] [Abstract][Full Text] [Related]
19. Extramedullary disease in APL: a real phenomenon to contend with or not?
Ganzel C; Douer D
Best Pract Res Clin Haematol; 2014 Mar; 27(1):63-8. PubMed ID: 24907018
[TBL] [Abstract][Full Text] [Related]
20. Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.
Imaizumi M; Tawa A; Hanada R; Tsuchida M; Tabuchi K; Kigasawa H; Kobayashi R; Morimoto A; Nakayama H; Hamamoto K; Kudo K; Yabe H; Horibe K; Tsuchiya S; Tsukimoto I
Br J Haematol; 2011 Jan; 152(1):89-98. PubMed ID: 20735397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
